What question did this study set out to answer?

Evaluate long-term outcomes of treat-and-extend regimen in treatment-naïve patients with macular edema from retinal vein occlusion.

April 13, 2026BMC Ophthalmology0 citationsOpen Access

Long-term disease control with anti-VEGF treat-and-extend treatment in macular edema due to retinal vein occlusion

SFSarah Fischer LHLaura Hoffmann KHK Hatz

Key Points

Evaluate long-term outcomes of treat-and-extend regimen in treatment-naïve patients with macular edema from retinal vein occlusion.
Conducted a retrospective analysis of patients treated with ranibizumab or aflibercept.
Included patients with macular edema secondary to branch or central retinal vein occlusion.
Measured best-corrected visual acuity, central retinal thickness, and treatment frequency over 12 months or longer.
BCVA improved significantly from baseline across four years (57.4 to 73.3 letters, p < 0.001).
CRT decreased significantly from baseline values over the four-year period (506 μm to 283 μm, p < 0.001).
Percentage of eyes with a dry retina increased from 46.2% at year 1 to 54.4% at year 3.

Abstract

This study aims to evaluate the long-term outcome of a treat-and-extend regimen (TER) in treatment-naïve patients with macular edema (ME) secondary to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO). A retrospective analysis was conducted on a consecutive series of patients treated with either ranibizumab 0.5 mg or aflibercept 2 mg in a treat-and-extend regimen without a loading dose with follow-up of at least 12 months. The evaluation included best-corrected visual acuity (BCVA), central retinal thickness (CRT), other morphological parameters assessed by spectral-domain optical coherence tomography (SD-OCT) and fluorescein angiography (FA) as well as treatment frequency. n = 106 (mean age 72.2 ± 11.2 years) were included, 55 BRVO and 51 CRVO/Hemi-CRVO. Mean follow-up period 54.1 ± 30.7 months (range 12–142). 36 eyes discontinued treatment: 9 eyes due to success and 27 lost to follow-up/death and 2 switched to Faricimab. BCVA significantly increased from 57.4 ± 23.9 letters at baseline to 72.6 ± 13.8 (p < 0.001), 72.3 ± 15.2 (p < 0.001), 72.4 ± 15.6 (p < 0.001), and 73.3 ± 13.5 letters (p < 0.001) after 1, 2, 3 and 4 years respectively. CRT significantly decreased from 506 ± 195 μm at baseline to 281 ± 72 μm (p < 0.001), 282 ± 64 μm (p < 0.001), 279 ± 72 μm (p < 0.001), and 283 ± 89 μm (p < 0.001), after 1, 2, 3 and 4 years, respectively. At year 1, 46.2% of eyes showed a dry retina (no intra- or subretinal fluid); at year 2, 48.0%; at year 3, 54.4%; and at year 4, 44.0%. Mean number of injections was 9.8 ± 2.2, 8.2 ± 2.5, 7.5 ± 3.1, and 7.3 ± 2.2 at years 1, 2, 3, and 4, respectively. The mean maximal recurrence-free treatment interval was 6.4 ± 2.1, 8.1 ± 2.7, 8.7 ± 2.8, and 8.5 ± 2.6 weeks within years 1, 2, 3, and 4, respectively. Long-term treat-and-extend regimen treatment using ranibizumab or aflibercept in treatment-naïve patients with CME due to BRVO or CRVO led to statistically significant and sustained functional and morphological improvements.

AIに質問

Bookmark

View Full Paper

Cite This Study

Fischer et al. (Sat,) studied this question.

synapsesocial.com/papers/69dc89473afacbeac03eb191 https://doi.org/https://doi.org/10.1186/s12886-026-04808-7

AIに質問

Bookmark

View Full Paper